News - Nerviano Medical Sciences

Nerviano Medical Sciences at BIO-Europe 2024

Nerviano Medical Sciences announces the participation in BIO Europe 2024…

We are speaking at the 15th Annual WADC San Diego 2024!

partnering event in
San Diego ,
4 – 7 Nov. 2024

Nerviano Medical Sciences announces publication of the paper “Present Scenario and Future Landscape of Payloads for ADCs: Focus on DNA-Interacting Agents”

We are pleased to announce the publication of our review article titled “Present Scenario and Future Landscape of Payloads for ADCs: Focus on DNA-Interacting Agents” in Pharmaceuticals…
(click the title for the full article)

NMS Group S.p.A. Announces Change in Shareholding Structure, Board of Directors and Statutory Auditors to Accelerate Growth and Innovation

NMS Group S.p.A. (NMS Group), the largest oncological R&D company in Italy, announces today a change to its shareholding structure, leading to a restructured board of directors and statutory auditors. The Fondazione Regionale per la Ricerca Biomedica (FRRB), established by the Lombardy Regional Government with an aim to promote and support biomedical research in the region, has agreed to conclude its investment in NMS Group as minority shareholder.

NMS-UPO paper featured on the cover of Chemistry A European Journal

Turning the Impossible into Reality …
(Click the title for the complete article)

Nerviano Medical Sciences Srl Announces BRAFTOVI® Royalty Agreement with Blue Owl Capital, potentially exceeding $80 Million

Nerviano Medical Sciences S.r.l. (NMS), a part of NMS Group S.p.A. (NMS Group) and Nerviano Medical Sciences, Inc., a wholly owned subsidiary of NMS S.r.l, focused on the discovery and development of oncology drugs and the largest oncological R&D company in Italy, today announced an agreement with funds managed by Blue Owl Capital (“Blue Owl”). This investment will enable NMS to monetize $80 million or more in potential future BRAFTOVI® royalties, with Blue Owl providing in excess of $50 million in upfront cash and contingent proceeds. Under the terms of the agreement, NMS retains all subsequent royalties tied to BRAFTOVI® ‘s global net sales once a specific multiple of Blue Owl’s investment has been met, which in NMS’s estimation are anticipated to exceed $30 million.

SIMIS Srl Appoints Marco Dieci as CEO to leverage and expand further opportunities at Nerviano Bio-Park

NMS Nerviano Bio-Park, today announced the appointment of Marco Dieci as the new Chief Executive Officer, effective immediately. With an exceptional track record in biotechnology, business development and entrepreneurship, Marco is ready to lead SIMIS and Nerviano Bio-Park into an era of unprecedented growth and collaboration.

Our scientists to speak at the SCI-2024 – XXVIII National Congress

We are honored to have two senior scientists speaking at the SCI-2024 – XXVIII National Congress in Milan. Elena Ardini: Wednesday, August 28th 8:30am - 9:00am Discovery of entrectinib: an amazing journey from target biology to innovative therapy (KN-028)...

Nerviano Medical Sciences announces publication of a research paper in “Chemistry – A European Journal”

Thrilled to announce that our latest paper, in collaboration with Prof. Gian Cesare Tron from Università del Piemonte Orientale (UPO), has just been published in the prestigious “Chemistry - A European Journal”! You can check it out here: link. This publication...

Nerviano Medical Sciences announces FDA protocol clearance of new IND application for NMS-812, a first-in-class dual inhibitor of PERK/GCN2. Brian Sherer, PhD. appointed to lead and accelerate the development.

NMS today announced that the United States Food and Drug Administration (FDA) has cleared the protocol for investigational new drug (IND) application for NMS-812, a first-in-class orally bioavailable and highly potent small molecule dual inhibitor of PERK/GCN2.